Founder: Susan Catalano

Year Founded: 2007

Year Partnered and Invested: 2014

NASDAQ listing: 2021

Exit: 2022

A novel approach to synaptic protection and restoration in Alzheimer’s disease.

Cognition Therapeutics is a clinical stage pharmaceutical company working on the discovery and development of small molecule therapeutics acting on novel targets to halt disease progression and improve symptoms in neurodegenerative disorders, including Alzheimer’s disease.

Founder Susan Catalano is an expert in synaptic plasticity, memory and learning, Alzheimer’s disease and the biology of protein oligomers, the toxic shapes of protein that underlie many neurodegenerative diseases.